Skip to main content
An official website of the United States government

Cancer Prevention Steering Committee

The NCI Cancer Prevention Steering Committee (CPSC) was established on May 25, 2017. The CPSC addresses the design, prioritization and evaluation of concepts for clinical trials to prevent cancer. The CPSC will review innovative cancer prevention, screening and surveillance concepts (i.e., phase 2 and phase 3 randomized trials) across a broad range of cancer and precancerous conditions in diverse patient populations that are seen within the NCI Community Oncology Research Program (NCORP).

The core committee membership includes representatives from NCORP Research Bases, prevention experts, R01 investigators, community oncologists, biostatisticians, patient advocates and NCI Staff. View the CPSC member roster.

Committee Activities

  • Evaluates and prioritizes cancer prevention, screening and surveillance clinical trial concepts for studies to be conducted through the NCORP mechanism
  • Evaluates proposals for the Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP) associated with cancer prevention clinical trial concepts
  • Convenes clinical trial planning meetings (CTPMs) to identify critical questions and prioritize key strategies related to cancer prevention, screening and surveillance
  • Reviews and updates strategic priorities for a given research area and reviews accrual to ongoing trials
  • Assesses the strength of the clinical trial portfolio and its alignment with the strategic priorities


For more information, contact NCI CCCT Program Director (Interim), Abdul Tawab Amiri, Ph.D., at